|
Prodrugs
|
D011355 |
[A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
] |
|
Complementarity Determining Regions
|
D12.776.543.750.705.816.824.300 |
|
|
Receptors, Antigen, T-Cell
|
D12.776.543.750.705.816.824 |
|
|
Lymphoma, B-Cell, Marginal Zone
|
C20.683.515.761.480.150.570 |
|
|
Motor Neuron Disease
|
C10.574.562 |
|
|
Neurodegenerative Diseases
|
C10.574 |
|
|
DNA Nucleotidylexotransferase
|
D08.811.913.696.445.308.325 |
|
|
DNA Nucleotidyltransferases
|
D08.811.913.696.445.308 |
|
|
Rudbeckia
|
B01.650.940.800.575.912.250.100.665 |
|
|
Basic Reproduction Number
|
D050936 |
[The expected number of new cases of an infection caused by an infected individual, amongst susceptible contacts only.
] |
|
Guanidinoacetate N-Methyltransferase
|
D050937 |
[This enzyme catalyzes the last step of CREATINE biosynthesis by catalyzing the METHYLATION of guanidinoacetate to CREATINE.
] |
|
Molecular Dynamics Simulation
|
G02.111.570.895 |
|
|
Nurses, Community Health
|
M01.526.485.650.655 |
|
|
Glycine N-Methyltransferase
|
D050938 |
[An enzyme that catalyzes the METHYLATION of GLYCINE using S-ADENOSYLMETHIONINE to form SARCOSINE with the concomitant production of S-ADENOSYLHOMOCYSTEINE.
] |
|
Gene Fusion
|
D050939 |
[The GENETIC RECOMBINATION of the parts of two or more GENES resulting in a gene with different or additional regulatory regions, or a new chimeric gene product. ONCOGENE FUSION includes an ONCOGENE as at least one of the fusion partners and such gene fusions are often detected in neoplastic cells and are transcribed into ONCOGENE FUSION PROTEINS. ARTIFICIAL GENE FUSION is carried out in vitro by RECOMBINANT DNA technology.
] |
|
Methyltestosterone
|
D04.210.500.054.079.429.824.664 |
|
|
Susac Syndrome
|
C10.597.825 |
|
|
Neoprene
|
D02.455.326.271.665.480 |
|
|
T-Lymphocytopenia, Idiopathic CD4-Positive
|
C20.673.627.800 |
|
|
Lymphopenia
|
C20.673.627 |
|
